Thermo Fisher Scientific Inc (NYSE: TMO)’s stock price has decreased by -2.94 compared to its previous closing price of 497.60. However, the company has seen a -6.10% decrease in its stock price over the last five trading sessions. businesswire.com reported 2025-04-01 that WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2025 before the market opens on Wednesday, April 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The.
Is It Worth Investing in Thermo Fisher Scientific Inc (NYSE: TMO) Right Now?
Thermo Fisher Scientific Inc (NYSE: TMO) has a price-to-earnings ratio that is above its average at 29.23x. The stock has a 36-month beta value of 0.87. Opinions on the stock are mixed, with 17 analysts rating it as a “buy,” 8 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for TMO is 376.61M, and at present, short sellers hold a 1.13% of that float. On April 02, 2025, the average trading volume of TMO was 1.94M shares.
TMO’s Market Performance
TMO stock saw a decrease of -6.10% in the past week, with a monthly decline of -7.77% and a quarterly a decrease of -8.19%. The volatility ratio for the week is 2.42%, and the volatility levels for the last 30 days are 2.24% for Thermo Fisher Scientific Inc (TMO). The simple moving average for the past 20 days is -6.26% for TMO’s stock, with a -13.94% simple moving average for the past 200 days.
Analysts’ Opinion of TMO
Many brokerage firms have already submitted their reports for TMO stocks, with Bernstein repeating the rating for TMO by listing it as a “Outperform.” The predicted price for TMO in the upcoming period, according to Bernstein is $630 based on the research report published on January 10, 2025 of the current year 2025.
TMO Trading at -10.46% from the 50-Day Moving Average
After a stumble in the market that brought TMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.08% of loss for the given period.
Volatility was left at 2.24%, however, over the last 30 days, the volatility rate increased by 2.42%, as shares sank -6.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.70% lower at present.
During the last 5 trading sessions, TMO fell by -6.10%, which changed the moving average for the period of 200-days by -16.11% in comparison to the 20-day moving average, which settled at $515.22. In addition, Thermo Fisher Scientific Inc saw -7.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMO starting from Boxer Michael A, who sale 3,775 shares at the price of $532.52 back on Mar 10 ’25. After this action, Boxer Michael A now owns 10,816 shares of Thermo Fisher Scientific Inc, valued at $2,010,537 using the latest closing price.
Boxer Michael A, the Officer of Thermo Fisher Scientific Inc, proposed sale 3,776 shares at $532.45 during a trade that took place back on Mar 10 ’25, which means that Boxer Michael A is holding shares at $2,010,537 based on the most recent closing price.
Stock Fundamentals for TMO
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.41 for the gross margin
The net margin for Thermo Fisher Scientific Inc stands at 0.15. The total capital return value is set at 0.09. Equity return is now at value 13.15, with 6.46 for asset returns.
Based on Thermo Fisher Scientific Inc (TMO), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.28. The debt to equity ratio resting at 0.63. The interest coverage ratio of the stock is 5.27.
Currently, EBITDA for the company is 11.54 billion with net debt to EBITDA at 2.38. When we switch over and look at the enterprise to sales, we see a ratio of 4.89. The receivables turnover for the company is 5.23for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.66.
Conclusion
To sum up, Thermo Fisher Scientific Inc (TMO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
